Scientific Communication
Rapid whole-blood immune profiling reveals heterogeneous HBV-specific T cell response patterns independent of clinical disease phases.
Nina Le Bert, Apostolos Koffas, Rajneesh Kumar, Floriana Facchetti, Anthony T. Tan, Upkar S. Gill, Lung-Yi Mak, Sophie W. Stretch, Tizong Miao, Smrithi Hariharaputran, Shou Kit Hang, Yifei Guo, Qi Chen, Elisabetta Degasperi, Pietro Lampertico, Wan Cheng Chow, Antonio Bertoletti, Patrick T.F. Kennedy
Background & Aims
There is an unmet need for immunological biomarkers in chronic HBV infection (CHB), where patient management relies on virological and biochemical markers despite the crucial role of virus-specific T cells in controlling viral replication and disease progression. Here, we developed the HBV-cytokine release assay (HBV-CRA), a rapid, point-of-care test, to define whether HBV-specific T cell functional patterns are linked with conventional disease phase classifications.
Methods
Peptides covering pan-genotype HBV proteomes were utilised to trigger cytokine release by HBV-specific T cells in whole blood. We first assessed the assay’s sensitivity by spiking whole blood with engineered HBV-specific T cells. Next, we compared the sensitivity and reproducibility of the HBV-CRA to ex vivo IFN-γ ELISpot assays. We then applied the assay in a cross-sectional study of 235 patients with CHB and longitudinally in patients with acute HBV infection (AHB) during HBsAg seroclearance.
Results
The HBV-CRA detected T cell function in 80% of CHB cases and showed that elevated IL-2 and IFN-γ levels after Core peptide stimulation were associated with HBsAg clearance in AHB. Unsupervised clustering identified distinct immune response patterns that were independent of established clinical and virological classifications, and detected a functional impact of NUC treatment on HBV-specific T cell responses.
Conclusions
The HBV-CRA is an easy-to-use assay that identifies immune profiles associated with HBsAg clearance in AHB and differentiates patients with CHB based on antiviral T cell function. Notably, distinct HBV-specific T cell cytokine patterns were detected independently of conventional clinical disease phases, suggesting that the HBV-CRA should guide the stratification of patients with CHB for immunotherapeutic interventions.
Impact and implications
Challenges in collecting anti-HBV immune biomarkers from patients with chronic HBV infection (CHB) have led us to develop an easy-to-use assay (HBV-CRA) designed to quantify virus-specific T cell function in patient whole blood. We show that the HBV-CRA can identify immune profiles associated with HBsAg clearance in AHB and reveal functional T cell heterogeneity among patients with CHB that is not captured by standard clinical classifications. By offering a scalable, point-of-care immune monitoring tool, the HBV-CRA could support the development and implementation of personalised immunotherapeutic strategies in CHB management.
The Impact of Hepatitis B Surface Antigen Reduction via Small Interfering RNA Treatment on Natural and Vaccine (BRII-179)-Induced Hepatitis B Virus-Specific Humoral and Cellular Immune Responses
Yun Ji, Nina Le Bert, Grace Lai-Hung Wong, Mark W. Douglas, Ariel Lee, Chong Zhu, Bing Wang, Jianxiang Lv, Dong Li, Ying Tan, Haiyan Ma, Jieliang Chen, Xiaofei Chen, Qing Zhu, Man-Fung Yuen, Antonio Bertoletti
Background & Aims
The impact of hepatitis B surface antigen (HBsAg) reduction from small interfering RNA (siRNA) treatments on hepatitis B virus (HBV)-specific immunity of individuals with chronic hepatitis B (CHB) has not been adequately analysed in humans. We conducted a phase 2a study treating CHB participants with nine 4-weekly doses of HBV-targeted siRNA elebsiran (BRII-835), either alone (n = 10) or in combination with a virus-like particle-based therapeutic vaccine (BRII-179) containing Pre-S1, Pre-S2, and S antigens, coadministered with (n = 39) or without (n = 41) interferon alfa.
Methods
We analysed longitudinally for 72 weeks virologic, clinical, and immunologic parameters, including HBsAg, alanine aminotransferase, hepatitis B surface antibody (anti-HBs), the neutralising activity of representative sera, and frequency and cytokine secretion ability of T cells specific for Pre-S1, Pre-S2, and S, both directly ex vivo and after in vitro expansion.
Results
Combination therapy with elebsiran and BRII-179 was well tolerated. Although no sustained HBsAg seroclearance or notable difference in mean HBsAg reduction was observed at the group level, we detected marked heterogeneity in immunologic responses among groups. HBsAg reduction mediated by siRNA alone was associated with minimal recovery of HBV-specific immune response. In contrast, the combination of elebsiran with BRII-179 induced a significant modification of immune responses, demonstrated by anti-HBs antibody production and an expansion of interleukin 2-producing helper T cells specific for Pre-S1/Pre-S2 antigens only. Importantly, anti-HBs antibodies persisted at a level of ≥100 IU/L in approximately 40% of participants for at least 32 weeks after combined treatment. Moreover, the neutralising ability of the anti–HBs–positive sera was correlated with HBsAg reduction.
Conclusions
siRNA-induced HBsAg reduction may contribute to the persistence and efficacy of the humoral arm of HBV-specific adaptive immunity in CHB participants receiving the therapeutic vaccine BRII-179.









